ACLX Quote, Financials, Valuation and Earnings

Gilead Sciences, Inc. has a net margin of -1127.12% compared to Arcellx, Inc.'s net margin of 27.55%. Arcellx, Inc.'s return on equity of -49.8% beat Gilead Sciences, Inc.'s return on equity of 41.72%.

Arcellx, Inc. has a consensus price target of $110.43, signalling downside risk potential of -2.92%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $155.15 which suggests that it could grow by 3.55%. Given that Gilead Sciences, Inc. has higher upside potential than Arcellx, Inc., analysts believe Gilead Sciences, Inc. is more attractive than Arcellx, Inc..

Arcellx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.360, suggesting its less volatile than the S&P 500 by 63.985%.

Arcellx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.11% to investors and pays a quarterly dividend of $0.79 per share. Arcellx, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 46.61% of its earnings as a dividend. Gilead Sciences, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Arcellx, Inc. quarterly revenues are $4.9M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.9B. Arcellx, Inc.'s net income of -$55.8M is lower than Gilead Sciences, Inc.'s net income of $2.2B. Notably, Arcellx, Inc.'s price-to-earnings ratio is -- while Gilead Sciences, Inc.'s PE ratio is 22.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx, Inc. is 176.15x versus 6.39x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Invivyd, Inc. has a net margin of -1127.12% compared to Arcellx, Inc.'s net margin of -79.75%. Arcellx, Inc.'s return on equity of -49.8% beat Invivyd, Inc.'s return on equity of -87.85%.

Arcellx, Inc. has a consensus price target of $110.43, signalling downside risk potential of -2.92%. On the other hand Invivyd, Inc. has an analysts' consensus of $10.00 which suggests that it could grow by 521.12%. Given that Invivyd, Inc. has higher upside potential than Arcellx, Inc., analysts believe Invivyd, Inc. is more attractive than Arcellx, Inc..

Arcellx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Invivyd, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Arcellx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Invivyd, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx, Inc. pays -- of its earnings as a dividend. Invivyd, Inc. pays out -- of its earnings as a dividend.

Arcellx, Inc. quarterly revenues are $4.9M, which are smaller than Invivyd, Inc. quarterly revenues of $13.1M. Arcellx, Inc.'s net income of -$55.8M is lower than Invivyd, Inc.'s net income of -$10.5M. Notably, Arcellx, Inc.'s price-to-earnings ratio is -- while Invivyd, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx, Inc. is 176.15x versus 4.26x for Invivyd, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -1127.12% compared to Arcellx, Inc.'s net margin of 20.83%. Arcellx, Inc.'s return on equity of -49.8% beat Johnson & Johnson's return on equity of 34.46%.

Arcellx, Inc. has a consensus price target of $110.43, signalling downside risk potential of -2.92%. On the other hand Johnson & Johnson has an analysts' consensus of $232.50 which suggests that it could fall by -5.43%. Given that Johnson & Johnson has more downside risk than Arcellx, Inc., analysts believe Arcellx, Inc. is more attractive than Johnson & Johnson.

Arcellx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.350, suggesting its less volatile than the S&P 500 by 64.977%.

Arcellx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.09% to investors and pays a quarterly dividend of $1.30 per share. Arcellx, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Arcellx, Inc. quarterly revenues are $4.9M, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Arcellx, Inc.'s net income of -$55.8M is lower than Johnson & Johnson's net income of $5.1B. Notably, Arcellx, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 22.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx, Inc. is 176.15x versus 6.34x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Relmada Therapeutics, Inc. has a net margin of -1127.12% compared to Arcellx, Inc.'s net margin of --. Arcellx, Inc.'s return on equity of -49.8% beat Relmada Therapeutics, Inc.'s return on equity of -214.4%.

Arcellx, Inc. has a consensus price target of $110.43, signalling downside risk potential of -2.92%. On the other hand Relmada Therapeutics, Inc. has an analysts' consensus of $9.67 which suggests that it could grow by 139.87%. Given that Relmada Therapeutics, Inc. has higher upside potential than Arcellx, Inc., analysts believe Relmada Therapeutics, Inc. is more attractive than Arcellx, Inc..

Arcellx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Relmada Therapeutics, Inc. has a beta of 0.766, suggesting its less volatile than the S&P 500 by 23.406%.

Arcellx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Relmada Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx, Inc. pays -- of its earnings as a dividend. Relmada Therapeutics, Inc. pays out -- of its earnings as a dividend.

Arcellx, Inc. quarterly revenues are $4.9M, which are larger than Relmada Therapeutics, Inc. quarterly revenues of --. Arcellx, Inc.'s net income of -$55.8M is lower than Relmada Therapeutics, Inc.'s net income of -$10.1M. Notably, Arcellx, Inc.'s price-to-earnings ratio is -- while Relmada Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx, Inc. is 176.15x versus -- for Relmada Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.